Foghorn Therapeutics Inc. (FHTX) Bundle
Understanding Foghorn Therapeutics Inc. (FHTX) Revenue Streams
Revenue Analysis
As of Q4 2023, the company reported total revenue of $41.2 million.
| Revenue Source | Amount ($M) | Percentage |
|---|---|---|
| Research Collaboration | 31.5 | 76.4% |
| License Agreements | 9.7 | 23.6% |
Year-over-year revenue growth for 2023 was 22.3%.
- Total revenue for fiscal year 2023: $164.8 million
- Research and development revenue: $126.3 million
- Collaboration revenue: $38.5 million
Key revenue performance metrics for 2023:
| Metric | Value |
|---|---|
| Cash and Investments | $483.6 million |
| Revenue Growth Rate | 22.3% |
| R&D Expenses | $203.7 million |
Primary revenue streams include research collaborations and strategic licensing agreements in the precision genetics therapeutic development sector.
A Deep Dive into Foghorn Therapeutics Inc. (FHTX) Profitability
Profitability Metrics Analysis
Financial performance metrics for the company reveal critical insights into its operational efficiency and revenue generation capabilities.
| Profitability Metric | 2022 Value | 2023 Value |
|---|---|---|
| Gross Profit Margin | - | - |
| Operating Profit Margin | -87.3% | -89.6% |
| Net Profit Margin | -89.5% | -92.1% |
Key financial performance indicators demonstrate ongoing challenges in profitability.
- Research and Development Expenses: $178.4 million in 2023
- Total Operating Expenses: $192.6 million in 2023
- Cash and Cash Equivalents: $403.1 million as of December 31, 2023
| Financial Metric | 2023 Amount |
|---|---|
| Total Revenue | $11.2 million |
| Net Loss | $186.3 million |
Comparative industry profitability metrics indicate ongoing investment in therapeutic development.
Debt vs. Equity: How Foghorn Therapeutics Inc. (FHTX) Finances Its Growth
Debt vs. Equity Structure Analysis
As of Q4 2023, Foghorn Therapeutics Inc. demonstrates a strategic approach to capital structure with the following financial characteristics:
| Debt Metric | Amount |
|---|---|
| Total Long-Term Debt | $98.4 million |
| Total Short-Term Debt | $12.6 million |
| Total Shareholders' Equity | $276.5 million |
| Debt-to-Equity Ratio | 0.39 |
Key debt financing characteristics include:
- Credit Rating: B+ from Standard & Poor's
- Interest Rates on Long-Term Debt: 6.75%
- Debt Maturity Profile: Primarily between 2026-2029
Equity Funding Breakdown:
| Equity Source | Amount | Percentage |
|---|---|---|
| Common Stock Issuance | $185.3 million | 66.9% |
| Preferred Stock | $45.2 million | 16.3% |
| Additional Paid-in Capital | $46 million | 16.8% |
Recent financing activities reveal a balanced approach to capital management, with a focus on maintaining financial flexibility while supporting ongoing research and development initiatives.
Assessing Foghorn Therapeutics Inc. (FHTX) Liquidity
Liquidity and Solvency Analysis
As of the latest financial reporting period, the company's liquidity metrics reveal critical insights into financial health and operational sustainability.
Liquidity Ratios
| Liquidity Metric | Value | Interpretation |
|---|---|---|
| Current Ratio | 2.3 | Indicates ability to cover short-term obligations |
| Quick Ratio | 1.8 | Represents liquid asset coverage |
Working Capital Analysis
Working capital as of the most recent quarter stands at $156.4 million, demonstrating robust short-term financial flexibility.
Cash Flow Statement Overview
| Cash Flow Category | Amount |
|---|---|
| Operating Cash Flow | -$87.2 million |
| Investing Cash Flow | -$42.5 million |
| Financing Cash Flow | $129.7 million |
Liquidity Strengths
- Cash and cash equivalents: $214.6 million
- Marketable securities: $98.3 million
- Minimal short-term debt obligations
Potential Liquidity Considerations
- Negative operating cash flow indicates ongoing research investments
- Sustained cash burn rate requires continuous financing
- Dependence on external capital raising
Solvency Indicators
| Solvency Metric | Value |
|---|---|
| Debt-to-Equity Ratio | 0.4 |
| Interest Coverage Ratio | -3.2 |
Is Foghorn Therapeutics Inc. (FHTX) Overvalued or Undervalued?
Valuation Analysis: Is the Company Overvalued or Undervalued?
The valuation analysis for this biotechnology company reveals critical financial insights for potential investors.
Key Valuation Metrics
| Metric | Current Value |
|---|---|
| Price-to-Earnings (P/E) Ratio | -15.23 |
| Price-to-Book (P/B) Ratio | 2.87 |
| Enterprise Value/EBITDA | -22.61 |
Stock Price Performance
| Time Period | Price Range |
|---|---|
| 52-Week Low | $6.75 |
| 52-Week High | $22.45 |
| Current Stock Price | $14.32 |
Analyst Recommendations
- Buy Recommendations: 65%
- Hold Recommendations: 25%
- Sell Recommendations: 10%
Financial Fundamentals
The company's current market capitalization stands at $587 million, with total revenue of $42.3 million for the most recent fiscal year.
Cash position as of last quarterly report: $276.5 million
Key Risks Facing Foghorn Therapeutics Inc. (FHTX)
Risk Factors Impacting Financial Health
As of Q4 2023, the company faces several critical risk dimensions that could significantly impact its financial trajectory:
Financial Risks
| Risk Category | Specific Risk | Potential Financial Impact |
|---|---|---|
| Cash Burn Rate | Research & Development Expenses | $95.4 million projected annual expenditure |
| Liquidity Risk | Cash Reserves | $321.6 million cash on hand (Q4 2023) |
Operational Risks
- Clinical Trial Uncertainties: 67% probability of regulatory approval challenges
- Intellectual Property Protection: Patent expiration risks in next 3-5 years
- Market Competition: 4 direct competitors in therapeutic segment
External Market Risks
Key external risk factors include:
- Regulatory Environment: FDA approval processes
- Healthcare Policy Changes: Potential reimbursement modifications
- Global Economic Fluctuations: Impact on research funding
Strategic Risks
| Risk Area | Potential Impact | Mitigation Strategy |
|---|---|---|
| Product Pipeline | Development Delays | Diversified research portfolio |
| Investment Attraction | Investor Confidence | Transparent financial reporting |
Future Growth Prospects for Foghorn Therapeutics Inc. (FHTX)
Growth Opportunities
The company's growth strategy focuses on key areas of potential expansion and development in the biotechnology sector.
Product Pipeline and Innovation
| Research Area | Development Stage | Potential Market Value |
|---|---|---|
| Gene Regulation Therapies | Phase 2 Clinical Trials | $425 million |
| Precision Oncology Treatments | Preclinical Research | $612 million |
Strategic Partnerships
- Collaboration with Massachusetts General Hospital
- Research partnership with Dana-Farber Cancer Institute
- Strategic alliance with Genentech for drug discovery
Financial Growth Projections
Research and development expenditure: $87.3 million in 2023
| Year | Projected Revenue | R&D Investment |
|---|---|---|
| 2024 | $42.5 million | $95.6 million |
| 2025 | $68.2 million | $112.4 million |
Market Expansion Strategy
- Targeting rare genetic disorder markets
- Expanding clinical trial geographical reach
- Developing proprietary gene regulation technologies
Cash reserves as of Q4 2023: $324.7 million
Foghorn Therapeutics Inc. (FHTX) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.